CARA THERAPUETICS RECRUITING STUDIES:

• CR845-310301 – CKD/Pruritus

This is a clinical trial testing oral difelikefalin to see if it helps reduce the intensity of itching and the impact that itching has on your quality of life. The study spans a duration of 16 weeks to 1 year.

Those meeting the eligibility criteria will receive trial-related procedures and the study medication without incurring any costs. Additionally, participants may be compensated for their time and travel. If deemed eligible, attendance of routine visits based on a specific schedule will be required.

ELI LILLY AND CO. RECRUITING STUDIES:

• J1I-MC-GZBU – T2DM/ Kidney Disease/ Overweight and Obesity

The main purpose of this study is to investigate the effect of retatrutide on renal function in participants with overweight or obesity and chronic kidney disease (CKD), with or without Type 2 Diabetes (T2D). The study will lasts around 31 weeks.

Those meeting the eligibility criteria will receive trial-related procedures and the study medication without incurring any costs. Additionally, participants may be compensated for their time and travel. If deemed eligible, attendance of routine visits based on a specific schedule will be required.

COMPLETED STUDIES:

  • AstraZeneca – D9183C0001 – DKD – 2023

  • Bayer – 16244(FIDELIO) – CKD – 2020

  • Bayer – 17530 (FIGARO) – DKD – 2021

  • CSL Behring – CSL346_2001 (MANEUVER) – DKD – 2022

  • Eli Lilly and Co. – H9X-MC-GBDX – T2DM / CKD – 2016

  • Ironwood Pharmaceuticals – C1973-203 – T2DM w/ Diabetic Nephropathy – 2019

  • Janssen Research & Development, LLC – 28431754DNE3001 (CREDENCE) – T2DM/Diabetic Nephropathy – 2018

  • Teijin America Inc. – TMX-049DN-201 – DKD – 2019

info@PlanItResearch.com